Treatment for Recurrent Ovarian Cancer—At First Relapse

Kimio Ushijima

doi:10.1155/2010/497429

Treatment for Recurrent Ovarian Cancer—At First Relapse

DOI PDF XML PubMed 被引用文献3件オープンアクセス

Kimio Ushijima

Department of OBGYN, Kurume University School of Medicine, 67 Asahi machi, Kurume 830-0011, Japan

書誌事項

公開日: 2010

権利情報

http://creativecommons.org/licenses/by/3.0/

DOI

10.1155/2010/497429

公開者: Hindawi Limited

この論文をさがす

CiNii Books

説明

<jats:p>Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although most patients receive standardized surgery and chemotherapy, the status of recurrent disease is heterogeneous. The site of recurrence and the survival intervals after recurrence are also widely distributed. Among a number of factors, many clinical trials identified time to recurrence was the factor most related to chemosensitivity at first relapse. The current recommendation for platinum sensitive ovarian cancer is a carboplatin containing combination chemotherapy. Generally, a single agent is chosen for platinum resistant ovarian cancer. Patients with single site recurrence and a long disease free interval are candidates for secondary cytoreduction, which may provide longer survival. There are several treatment choices at first relapse, and disease status, chemotherapy-free interval, and the patient's condition play a major role in the decision making process.</jats:p>